A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects  .

CONCLUSION: This study demonstrated the similarity of PK, immunogenicity, and safety profiles of IBI305 to those of bevacizumab. . PMID: 30663977 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30663977?dopt=Abstract

Source: International Journal of Clinical Pharmacology and Therapeutics - January 25, 2019 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research

More News: Avastin | China Health | Drugs & Pharmacology | Study

A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects .

A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects  .